Discover
OBIO
Orchestra BioMed Holdings, Inc.
4.30
2 x 3.14
2 x 5.42
bid
ask
-
0.02
0.35%
2 @ 04:00 PM
4.30 +0.00 (0.00%)
| Ytd | 3.61% | |
| 1y | 55.23% |
4.21
day range
4.36
2.20
52 week range
5.42
| Open | 4.29 | Prev Close | 4.32 | Low | 4.21 | High | 4.36 | Mkt Cap | 257.49M |
| Vol | 267.08K | Avg Vol | 313.35K | EPS | -0.95 | P/E | N/A | Forward P/E | -2.66 |
| Beta | 0.41 | Short Ratio | 12.51 | Inst. Own | 54.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.03 | 200-d Avg | 4.03 | 1yr Est | 15.60 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.44 | -0.41 | 0.03 | 6.82% |
| 2024-08-12 | 2024-06 | -0.41 | -0.45 | -0.04 | -9.76% |
| 2024-08-12 | 2024-06 | -0.41 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.4 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.4 | -0.38 | 0.02 | 5.00% |
| 2024-03-27 | 2023-12 | -0.38 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-13 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-08-22 | HC Wainwright & Co. | Upgrade | Buy | |
| 2024-07-25 | B. Riley Securities | Upgrade | Buy | |
| 2024-06-12 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-03-28 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-19 | ARYEH JASON M | Director | 68.36K | Stock Award(Grant) |
| 2024-06-19 | CONNEALY PAMELA ANN | Director | 21.29K | Stock Award(Grant) |
| 2024-09-09 | FAIN ERIC S | Director | 0.00 | Sale |
| 2024-12-17 | HOCHMAN DAVID P | Chief Executive Officer | 919.64K | Purchase |
| 2024-05-29 | LITTLE WILLIAM REED | Officer | 307.86K | Purchase |
| 2024-05-07 | MIKA YUVAL | Officer | 158.91K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RTW Investments LP | 8.21M | 38.49M | 21.59% |
| 2024-09-29 | Perceptive Advisors Llc | 4.59M | 21.54M | 12.08% |
| 2024-09-29 | Blackrock Inc. | 1.94M | 9.11M | 5.11% |
| 2024-09-29 | Vanguard Group Inc | 1.31M | 6.14M | 3.45% |
| 2024-09-29 | Geode Capital Management, LLC | 567.22K | 2.66M | 1.49% |
| 2024-09-29 | Price (T.Rowe) Associates Inc | 512.66K | 2.40M | 1.35% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 698.14K | 3.27M | 1.84% |
| 2024-10-30 | iShares Russell 2000 ETF | 520.42K | 2.44M | 1.37% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 414.59K | 1.94M | 1.09% |
| 2024-09-29 | Price (T.Rowe) Health Sciences Fund | 344.99K | 1.62M | 0.91% |
| 2024-08-30 | Blackrock Funds-Health Sciences Opportunity Portfolio | 262.31K | 1.23M | 0.69% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 237.96K | 1.12M | 0.63% |